ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

DRMA vs APVO // ENTERPRISE SCALE & MARKET CAP

Dermata Therapeutics Inc. (NASDAQ) VS. Aptevo Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: DRMA 2 — APVO 1
▲ ENTERPRISE SCALE & MARKET CAP LEADER: DRMA
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DRMA VS. APVO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC DRMA APVO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 2/9 -1.00 APVO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.1 29.1 +11.00 DRMA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap ACTIVE $3.7M $3.6M $137.2K DRMA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR DRMA REV APVO REV DRMA GROSS % APVO GROSS % DRMA FCF APVO FCF
FY 2025 $21.8M $73.7M — — -$7.8M -$25.6M
FY 2024 $35.0M $68.9M — — -$11.2M -$23.8M
FY 2023 $22.5M $80.9M — — -$6.4M -$11.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DRMA // BETA —
APVO // BETA —